


Population: patients with metastatic PDAC and *KRAS*G12D mutation

Phase 3
ClinicalTrials.gov ID: NCT07522073
Study ID: DAWN-303 (INCB161734-303)



^a Investigator's choice between 2 standard chemotherapy regimens: mFOLFIRINOX or GnP.

PRIMARY ENDPOINTS

ORR by BICR per RECIST 1.1

PFS by BICR per RECIST 1.1

OS

SECONDARY ENDPOINTS

DOR by BICR and INV

DCR by BICR and INV

PFS by INV

ORR by INV

Incidence of TEAEs

Incidence of TEAEs leading to treatment interruption, dose reductions, or discontinuation

Change in health-related quality-of-life assessments

SELECT INCLUSION CRITERIA

- ≥18 years of age
- Histologically or cytologically confirmed metastatic PDAC with a locally determined *KRAS*G12D mutation
- No prior systemic therapy for metastatic disease
- Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1
- Adequate organ function

SELECT EXCLUSION CRITERIA

- Prior treatment with any KRAS inhibitor
- Chronic or current active infectious disease requiring systemic treatment within 1 week prior to the first dose of study drug
- Known active CNS metastases

The efficacy and safety of the investigational compound discussed has not been established. There is no guarantee that this compound will become commercially available for the use under investigation.

For more information, visit **IncyteClinicalTrials.com** or contact us at **1-855-4MED-INFO (855-463-3463)** or **clintrials@incyte.com**

A copy of this panel can be accessed using the QR code:



1L, first line; BICR, blinded independent central review; CNS, central nervous system; DCR, disease control rate; DOR, duration of response; GnP, gemcitabine + nab-paclitaxel; INV, investigator; KRAS, KRAS proto-oncogene, GTPase; mFOLFIRINOX, modified leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin; ORR, objective response rate; OS, overall survival; PD, progressive disease; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival; PS, performance status; R, randomized; RECIST, Response Evaluation Criteria in Solid Tumors; TEAE, treatment-emergent adverse event.

1. ClinicalTrials.gov. Accessed Aug 2026. <https://clinicaltrials.gov/study/NCT07522073> 2. Wainberg Z, et al. ASCO-GI 2026. Abstract 654.